Page 1

Innocan Pharma Announces Second Quarter Fiscal year 2026 Results , With Revenue of US $ 5.25M ( CAD 7.3M ) Second Quarter 2026 Results : Gross Margin of 90.9 % and Category Leadership HERZLIYA , Israel and CALGARY , Alberta , Aug. 31 , 2026 / CNW / -- Innocan Pharma Corporation ( CSE : INNO ) ( OTCQB : INNPF ) ( " Innocan " or the " Company " ) , today reported today 2026 financial consolidated results for the six and three months ended June 30 , 2026 . INNOCAN PHARMA Innocan's consumer wellness subsidiary . B.I. Sky Global Ltd. ( " BI Sky " ) , successfully maintained a gross margin of 90.9 % during the period , reflecting the strength of its product portfolio , direct - to - consumer business model and disciplined approach to operations . VALITIC ™ Maintains Leading Amazon Best Seller Position VALITIC ™ , the flagship skincare brand of B.I. Sky , continues to maintain a leading positions across key product categories on Amazon , including achieving the leading ranking in its category . This performance reflects continued consumer demand and the growing strength of the VALITIC ™ brand . VALITIC ™ continues to hold Amazon's " Best Seller " badge , recognizing its position as the Top best - selling product in its specific category . The badge is based on actual sales performance rather than customer ratings and is updated hourly according to sales volume , highlighting the brand's strong and sustained consumer demand . VALITIC ™ also holds Amazon's Choice recognition , reflecting Amazon's algorithmic recommendation based on factors including customer ratings , price competitiveness , availability , delivery performance and return rates . " We are proud of the strength of BI Sky's business and the consumer trust built around our products , " said Iris Bincovich , CEO of Innocan Pharma Corporation . The Company's results were also impacted by the Trump administration's frequently changing policies regarding customs duties and tariffs , which created significant uncertainty that led to a decline in sales in the period . However , the Company continues to maintain a strong balance sheet and solid liquidity position , with approximately $ US 6.4 million in cash and cash equivalents and $ US10.37 million in total assets as of June 30 , 2026 , providing a solid consolidated financial foundation to support its ongoing operations and growth initiatives . Roni Kamhi , CEO of B.I. Sky and COO of Innocan Pharma said " Building on Our Top Amazon Ranking to Expand Sales Across Multiple Channels B.I. Sky is advancing initiatives to diversify and expand its sales channels , building on its leading position on Amazon while broadening its market reach across multiple platforms . Amazon will continue to represent an important sales channel . At the same time , the Company is pursuing additional growth opportunities , including expanding its relationships with major U.S. retail and distribution networks and increasing its presence across major online retail platforms . In parallel , B.I. Sky has begun selling through its own direct - to - consumer ( DTC ) website , which is already operational and provides an additional platform to build direct relationships with consumers , strengthen brand engagement , and expand the reach of the ValiticⓇ brand . I believe that its established brands , product portfolio and existing customer base provide a strong foundation for further growth . By leveraging these strengths across a broader range of sales channels , the Company aims to increase market reach , create additional revenue opportunities and strengthen its commercial performance . I expect these initiatives to support revenue growth and expand the reach and visibility of its brands over the coming year . " With a greater focus on sales execution , broader distribution and continued investment in our core strengths , we believe B.I. Sky is well positioned to strengthen its commercial performance and create long - term value for our shareholders , " concluded Mr. Kamhi . FISCAL 2026 THREE MONTHS SELECT FINANCIAL RESULTS ( unaudited ) Consolidated Three Months Ended June 30 , ( US $ in millions ) 2026 Revenues Gross Profit 5.25 4.769 2025 7.01 6.195 Percentage Change ( 25.06 % ) ( 23.0 % ) 0.396 ( 228.3 % ) Gross Margin 90.8 % 88.4 % Operating Profit ( Loss ) ( 0.508 ) • Revenues totaled US $ 5.25 million for the three months ended June 30 , 2026 , On a year - over - year basis , revenues decreased 25.06 % compared to the same period in the prior year . • Gross Profit totaled US $ 4.769 million representing a decrease of 23.0 % on a reported basis for the three months ended June 30 , 2026 . • Gross Margin remained high at 90.8 % despite the decline in revenues in three months ended June 30 , 2026 . • Operating loss totaled US $ 0.508 million , representing an increase of 228.3 % on a reported basis for the three months ended June 30 , 2026 . The Company's full set of unaudited condensed interim consolidated financial statements for the three and six months ended June 30 , 2026 , and accompanying management's discussion and analysis can be accessed by visiting the Company's website at www.innocanpharma.com and its SEDAR + profile at www.sedarplus.ca . About Innocan : Innocan is an innovator in the pharmaceuticals and wellness sectors . In the wellness sector , Innocan develops and markets a wide portfolio of high - performance self - care and beauty products to promote a healthier lifestyle . Under this segment Innocan carries on business through its 60 % owned subsidiary , BI Sky Global Ltd. , which focuses on advanced , targeted online sales . www.innocanpharma.com Contact Information : For Innocan Pharma Corporation : Iris Bincovich , CEO +1 5162104025 + 972-54-3012842